Accelerating Therapeutic DiscoveryTM

News From The Alpha-1 Project

Entries for March 2013

26

MIAMI, FL and GAINESVILLE, FL (March 26, 2013) - The Alpha-1 Project (TAP) today announced its first investment in a potential new treatment for Alpha-1 Antitrypsin Deficiency (Alpha-1), the most common known genetic risk factor for emphysema. TAP is partially funding further trials of a gene therapy treatment being developed by Applied Genetic Technologies Corporation (AGTC).

Alpha-1 is a genetic disorder characterized by low levels of or absent alpha-1 antitrypsin protein in the blood. Alpha-1 patients are at risk for severe lung disease as adults and liver disease at any age. Up to 3% of all people diagnosed with COPD may have undetected Alpha-1. The condition can lead to severe disability and reduced life expectancy.

[Read More...]